⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 13, 2025The Lancet HaematologyOpen Access

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Janssen.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chari et al. (2025) studied this question.

synapsesocial.com/papers/691ccb05f026b07951118784 https://doi.org/10.1016/s2352-3026(24)00385-5

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE StudyCross-Sectional Study · 2021 · 23 citations
2Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myelomaPrognostic Study · 2012 · 128 citations
3Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab2024 · 49 citations
4Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 StudyEarly-Phase Clinical Trial · 2023 · 6 citations
5Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple MyelomaOriginal Research · 2019 · 80 citations